Exelixis reported $15.92M in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.41M 277K
Agios Pharmaceuticals AGIO:US USD 413K 104K
Akebia Therapeutics AKBA:US USD -11252000 40.93M
Amgen AMGN:US USD 1.75B 159M
AstraZeneca AZN:LN USD 2.51B 393M
Bayer BAYN:GR EUR 4.77B 521M
Biomarin Pharmaceutical BMRN:US USD 127.29M 11M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Eisai 4523:JP JPY 46.74B 1.6B
Eli Lilly And LLY:US USD 1.55B 31M
Esperion Therapeutics ESPR:US USD 4.16M 2.35M
Exelixis EXEL:US USD 15.92M 615K
Glaxosmithkline GSK:US GBP 2.18B 209M
MacroGenics MGNX:US USD 1.79M 1.35M
Merk MRK:US USD 3.36B 519M
Moderna Inc MRNA:US USD 1.92B 818M
Nektar Therapeutics NKTR:US USD 6.23M 1.26M
Neurocrine Biosciences NBIX:US USD 7.7M 1.6M
Novartis NOVN:VX USD 3.84B 180M
Pfizer PFE:US USD 9.82B 3.73B
Puma Biotechnology PBYI:US USD 16.84M 4.34M
Seattle Genetics SGEN:US USD 108.21M 88K
Takeda 4502:JP JPY 335.97B 30.53B
Ultragenyx Pharmaceutical RARE:US USD 5.32M 3.31M
YTE INCY:US USD 53.76M 4.48M